Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
96.5 GBX | -1.03% | -1.53% | +10.92% |
Apr. 02 | Roadside shares suspended; Adnams looks for funds | AN |
Mar. 21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
Sales 2023 * | 23.89M 29.91M | Sales 2024 * | 29.61M 37.08M | Capitalization | 81.5M 102M |
---|---|---|---|---|---|
Net income 2023 * | -1M -1.25M | Net income 2024 * | -2M -2.5M | EV / Sales 2023 * | 2.74 x |
Net cash position 2023 * | 16.13M 20.19M | Net cash position 2024 * | 13.48M 16.88M | EV / Sales 2024 * | 2.3 x |
P/E ratio 2023 * |
-57.2
x | P/E ratio 2024 * |
-51.1
x | Employees | 151 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 65.46% |
Latest transcript on Diaceutics PLC
1 day | -1.03% | ||
1 week | -1.53% | ||
Current month | -2.53% | ||
1 month | -7.21% | ||
3 months | -3.98% | ||
6 months | +11.56% | ||
Current year | +10.92% |
Managers | Title | Age | Since |
---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 40 | 08-05-31 |
Nick Roberts
DFI | Director of Finance/CFO | - | 22-03-17 |
Julie Browne
COO | Chief Operating Officer | - | 22-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Graham Paterson
BRD | Director/Board Member | - | 23-09-30 |
Deborah Davis
CHM | Chairman | 61 | 21-01-03 |
Peter Keeling
BRD | Director/Board Member | 63 | 04-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 96.5 | -1.03% | 42,451 |
24-05-09 | 97.5 | 0.00% | 86,754 |
24-05-08 | 97.5 | 0.00% | 47,644 |
24-05-07 | 97.5 | -0.51% | 14,920 |
24-05-03 | 98 | -1.51% | 62,677 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.92% | 102M | |
+16.85% | 4.48B | |
-21.41% | 2.27B | |
+20.89% | 1.89B | |
-5.42% | 1.67B | |
+0.03% | 1.57B | |
-20.35% | 1.52B | |
-30.74% | 1.24B | |
-8.07% | 1.16B | |
-12.05% | 968M |
- Stock Market
- Equities
- DXRX Stock